GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » Total Equity

RGTLF (Argent Biopharma) Total Equity : $-6.89 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Argent Biopharma Total Equity?

Argent Biopharma's total equity for the quarter that ended in Dec. 2024 was $-6.89 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Argent Biopharma Total Equity Historical Data

The historical data trend for Argent Biopharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma Total Equity Chart

Argent Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.14 6.86 7.77 -5.46 -3.87

Argent Biopharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.95 -5.46 0.45 -3.87 -6.89

Argent Biopharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Argent Biopharma's Total Equity for the fiscal year that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=7.163-11.031
=-3.87

Argent Biopharma's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=1.937-8.828
=-6.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma Total Equity Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Argent Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (OTCPK:RGTLF) » Definitions » Total Equity
Comparable Companies
ASX:EOF ASX:IVX ASX:AGH ASX:EXL ASX:PER ASX:CAN ASX:BP8 ASX:ECS ASX:NXS ASX:LGP ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
H5O0:Germany RGT:Australia
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Website
https://www.argentbiopharma.com
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.